Abstract
Mesothelin (MSLN) has been found to be highly expressive in multiple solid tumors including lung cancer. We engineered autocrine PD-1 nano antibodies MSLN CAR-T cells (aPD1-MSLN-CART), targeting MSLN positive tumor cells by chimeric antigen receptor-modified T (CAR-T) cells as well as secretion of PD1 antibodies, playing dual antitumor immune mechanism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
